DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.72
−2.04%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 38.11x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.77x
- Price / sales
- 874.64x
- Price / cash flow
- -7.26x
Enterprise value
- Enterprise value
- $2.5B
- EV / sales
- 685.13x
- EV / EBITDA
- -4.97x
- EV / EBIT
- -4.55x
- Market cap
- $3.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026